Tune in to The Medicine Box Podcast as CNBC-TV18's Ekta Batra gets in conversation with Biocon chairperson Kiran Mazumdar Shaw about Semglee, the first interchangeable biosimilar insulin product to have received approval from the US drugs regulator.
In a significant development this year, the US Food and Drug Administration granted interchangeable status to two biosimilar drugs — Biocon's diabetes drug insulin glargine branded as Semglee and Boehringer Ingelheim’s biosimilar Cyltezo.
In this edition of The Medicine Box Podcast season 5, CNBC-TV18's Ekta Batra speaks to Kiran Mazumdar-Shaw, chairperson of pharma major Biocon, who explains the concept of interchangeability and whether it is changing the Biosimilar market. Mazumdar-Shaw talks about Semglee, the first interchangeable biosimilar insulin product, which has received approval from the US drug regulator for treatment of diabetes.
Interchangeability essentially means a pharmacist in the US can give a person the drug approved with an interchangeable status other than reference biologic on prescription. The development possibly paves the way for more life-saving drugs seeing greater accessibility and reducing price.
Shaw also talks about Cyltezo, which is the biosimilar version of one of the world’s largest selling biologic drugs Humira, used for arthritis and other conditions.
Tune in to The Medicine Box Podcast to find out more about interchangeable biosimilars, their competition, prices, and more.